Medicine guide
Famotidine
20 mg · Tablet, Film Coated
- Prescription only
- Histamine-2 Receptor Antagonist
- Active substance
- Famotidine
- Made by
- Redpharm Drug
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
At a glance
Quoted from the official label · 2025-12-02
What it is
Histamine-2 Receptor Antagonist
Used for
- Active duodenal ulcer (DU).
The label’s usual adult dose
Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily
Full directions ↓Do not take it if
Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H 2 ) receptor antagonists.
All warnings ↓Good to know
- Prescription only
- FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed
What it is for
Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:
- active duodenal ulcer (DU).
- active gastric ulcer (GU).
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in
- adults for the:
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ):
- In adult and pediatric patients 40 kg and greater for the treatment of:
- active duodenal ulcer (DU).
- active gastric ulcer.
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the:
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of DU recurrence.
From the official label · 2025-12-02 · DailyMed
How it works
From this product’s own US prescribing label.
Famotidine is a competitive inhibitor of histamine-2 (H 2 ) receptors.
The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion.
Half-life2.5–3.5 h
Mostly cleared after≈ 15 hfive half-lives — our arithmetic
How it leaves the body
Famotidine is eliminated by renal (65 to 70%) and metabolic (30 to 35%) routes.
With food
Bioavailability may be slightly increased by food, or slightly decreased by antacids; however, these effects are of no clinical consequence.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-12-02
Do not take it if
- Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H 2 ) receptor antagonists.
- History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H 2 receptor antagonists.
- ( 4 )
Quoted from the official label, section “Contraindications”.
How to take it
These directions are for this exact strength and form. Another one is different.
- Indication Recommended Dosage ( 2.1 ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily
- Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily
- See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( 2.1 , 2.2 ) Administration ( 2.3 ) :
- Take once daily before bedtime or twice daily in the morning and before bedtime with or without food. 2.1 Recommended Dosage Table 1 shows the recommended dosage of famotidine 20 mg and 40 mg tablets in adult and pediatric patients weighing 40 kg and greater with normal renal function. The use of famotidine 20 mg and 40 mg tablets is not recommended in pediatric patients weighing less than 40 kg because the lowest available strength (20 mg) exceeds the recommended dose for these patients. Use another famotidine formulation for pediatric patients weighing less than 40 kg. Table 1:
- Recommended Dosage and Duration of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Normal Renal Function Indication Recommended Dosage Recommended Duration Active duodenal ulcer (DU) 40 mg once daily; or 20 mg twice daily a Up to 8 weeks b,c Active gastric ulcer 40 mg once daily Up to 8 weeks c Symptomatic nonerosive GERD 20 mg twice daily Up to 6 weeks c Erosive esophagitis diagnosed by endoscopy 20 mg twice daily; or 40 mg twice daily a Up to 12 weeks Pathological hypersecretory conditions d Starting dosage:
- 20 mg every 6 hours; adjust dosage to individual patient needs Maximum dosage 160 mg every 6 hours As clinically indicated Reduction of the risk of DU recurrence d 20 mg once daily 1 year c or as clinically indicated a Both dosages demonstrated effectiveness in clinical trials [ see Clinical Studies (14) ]. b In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 weeks, consider an additional 2 to 4 weeks of treatment [ see Clinical Studies (14.1) ]. c Longer treatment durations have not been studied in clinical trials [see Clinical Studies ( 14.1 , 14.2 , 14.3 )]. d In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [ see Use in Specific Populations (8.4) ]. 2.2 Dosage in Renal Impairment Dosage adjustments of famotidine tablets are recommended for patients with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) [ see Use in Specific Populations (8.6) ]. Table 2 shows the recommended maximum dosage of famotidine 20 mg or 40 mg tablets for patients with renal impairment, by indication. Use the lowest effective dose. Some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension, lower dose tablet). Table 2:
- Recommended Maximum Dosage of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Moderate and Severe Renal Impairment Indication Recommended Maximum Dosages Creatinine clearance 30 to 60 mL/minute Creatinine clearance less than 30 mL/minute Active duodenal ulcer (DU) 20 mg once daily; or 40 mg every other day 20 mg every other day a Active gastric ulcer 20 mg once daily; or 40 mg every other day 20 mg every other day a Symptomatic nonerosive GERD 20 mg once daily 20 mg every other day a Erosive esophagitis diagnosed by endoscopy b 20 mg once daily; or 40 mg every other day b 20 mg every other day a,b 40 mg once daily b 20 mg once daily b Pathological hypersecretory conditions c
- Avoid use d Reduction of the risk of DU recurrence c 20 mg every other day a (see footnote) e a An alternate dosage regimen is 10 mg once daily. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. b Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [ see Clinical Studies (14.4) ]. c In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [ see Use in Specific Populations (8.4) ]. d Doses required to treat pathological hypersecretory conditions may exceed the maximum doses evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine tablets for pathological hypersecretory conditions is unknown. e Recommended dosage regimen is 10 mg every other day. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. 2.3 Administration Instructions
- Take famotidine tablets once daily before bedtime or twice daily in the morning and before bedtime, as recommended.
- Famotidine tablets may be taken with or without food [ see Clinical Pharmacology (12.3) ].
- Famotidine tablets may be given with antacids.
Quoted from the official label, section “Dosage & Administration”.
Other warnings
- Elderly patients and patients with renal impairment at increased risk; reduce the dosage. ( 2.2 , 5.1 , 8.5 , 8.6 )
- GI Malignancy :
- Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy. ( 5.2 ) 5.1 Central Nervous System Adverse Reactions Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with famotidine. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function, dosage adjustments are recommended in patients with renal impairment [ see Dosage and Administration (2.2) , Clinical Pharmacology (12.3) ]. 5.2 Concurrent Gastric Malignancy In
- adults, symptomatic response to therapy with famotidine does not preclude the presence of gastric malignancy. Consider evaluation for gastric malignancy in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with famotidine.
Quoted from the official label, section “Warnings”.
Pregnancy and breastfeeding
- Risk Summary Available data with H 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- In animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see Data).
- The estimated background risk for major birth defects and miscarriage for the indicated population is unknown.
- All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
- In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
- Data Animal Data Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine.
- While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg per day, based on body surface area) or higher.
- There are, however, no adequate or well-controlled studies in pregnant women.
- Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
- IN SPECIFIC POPULATIONS
- Geriatric Use :
- Use the lowest effective dose for an elderly patient and monitor renal function. ( 2.2 , 5.1 , 8.5 )
- Renal Impairment :
- Risk of CNS adverse reactions and QT prolongation in patients with moderate and severe renal impairment; reduce the dosage. ( 2.2 , 8.6 ) 8.1 Pregnancy Risk Summary Available data with H 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see Data). The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg per day, based on body surface area) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. 8.2 Lactation Risk Summary There are limited data available on the presence of famotidine in human breast milk. There were no effects on the breastfed infant. There are no data on famotidine effects on milk production. Famotidine is present in the milk of lactating rats (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for famotidine and any potential adverse effects on the breastfed child from famotidine or from the underlying maternal condition. Data Animal Data Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of famotidine at least 600 times the usual human dose. 8.4 Pediatric Use The safety and effectiveness of famotidine have been established in pediatric patients for the treatment of peptic ulcer disease (i.e., duodenal ulcer, gastric ulcer) and GERD (i.e., symptomatic nonerosive GERD, erosive esophagitis as diagnosed by endoscopy). The use of famotidine and the recommended dosage of famotidine in these pediatric patients is supported by evidence from adequate and well-controlled studies of famotidine in
- adults and published pharmacokinetic and pharmacodynamic data in pediatric patients [ see Dosage and Administration (2.1) , Clinical Pharmacology (12.2 , 12.3) ] . In pediatric patients, the safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established. Famotidine 20 and 40 mg tablets are not recommended for use in pediatric patients weighing less than 40 kg because these tablet strengths exceed the recommended dose for these patients [ see Dosage and Administration (2.1) ] . For pediatric patients weighing less than 40 kg, consider another famotidine formulation (e.g., oral suspension, lower dose tablet). 8.5 Geriatric Use Of the 1442 famotidine-treated patients in clinical studies, approximately 10% were 65 and older. In these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients. In postmarketing experience, CNS adverse reactions have been reported in elderly patients with and without renal impairment receiving famotidine [ see Warnings and Precautions (5.1) ]. Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to famotidine may be greater in elderly patients, particularly those with impaired renal function [ see Use in Specific Populations (8.6) ]. In general, use the lowest effective dose of famotidine for an elderly patient and monitor renal function [ see Dosage and Administration (2.2) ]. 8.6 Renal Impairment CNS adverse reactions and prolonged QT intervals have been reported in patients with moderate and severe renal impairment [ see Warnings and Precautions (5.1) ] . The clearance of famotidine is reduced in
- adults with moderate and severe renal impairment compared to
- adults with normal renal function [ see Clinical Pharmacology (12.3) ] . No dosage adjustment is needed in patients with mild renal impairment (creatinine clearance greater than or equal to 60 mL/minute). Dosage reduction is recommended in adult and pediatric patients greater than or equal to 40 kg with moderate or severe renal impairment (creatinine clearance less than 60 mL/minute) [ see Dosage and Administration (2.2) ].
Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.
Other medicines
- Drugs Dependent on Gastric pH for Absorption :
- Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy. See full prescribing information for a list of interacting drugs. ( 7.1 )
- Tizanidine (CYP1A2) Substrate :
- Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness;
- avoid concomitant use, if possible. ( 7.2 ) 7.1 Drugs Dependent on Gastric pH for Absorption Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug. Concomitant administration of famotidine with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir is not recommended. See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine. 7.2 Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate.
- Avoid concomitant use with famotidine. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness. Refer to the full prescribing information for tizanidine.
Quoted from the official label, section “Drug Interactions”.
If you take too much
In an emergency, call your local emergency number or a poison control centre.
- The types of adverse reactions in overdosage of famotidine are similar to the adverse reactions encountered with use of recommended dosages [ see Adverse Reactions (6.1) ] .
- In the event of overdosage, treatment should be symptomatic and supportive.
- Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed.
- Due to low binding to plasma proteins, famotidine is eliminated by hemodialysis.
- There is limited experience on the usefulness of hemodialysis as a treatment for famotidine overdosage.
Quoted from the official label, section “Overdosage”.
Use in children
- The safety and effectiveness of famotidine have been established in pediatric patients for the treatment of peptic ulcer disease (i.e., duodenal ulcer, gastric ulcer) and GERD (i.e., symptomatic nonerosive GERD, erosive esophagitis as diagnosed by endoscopy).
- The use of famotidine and the recommended dosage of famotidine in these pediatric patients is supported by evidence from adequate and well-controlled studies of famotidine in
- adults and published pharmacokinetic and pharmacodynamic data in pediatric patients [ see Dosage and Administration (2.1) , Clinical Pharmacology (12.2 , 12.3) ] .
- In pediatric patients, the safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established.
- Famotidine 20 and 40 mg tablets are not recommended for use in pediatric patients weighing less than 40 kg because these tablet strengths exceed the recommended dose for these patients [ see Dosage and Administration (2.1) ] .
- For pediatric patients weighing less than 40 kg, consider another famotidine formulation (e.g., oral suspension, lower dose tablet).
Quoted from the official label, section “Pediatric Use”.
Use in older people
- Of the 1442 famotidine-treated patients in clinical studies, approximately 10% were 65 and older.
- In these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients.
- In postmarketing experience, CNS adverse reactions have been reported in elderly patients with and without renal impairment receiving famotidine [ see Warnings and Precautions (5.1) ].
- Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to famotidine may be greater in elderly patients, particularly those with impaired renal function [ see Use in Specific Populations (8.6) ].
- In general, use the lowest effective dose of famotidine for an elderly patient and monitor renal function [ see Dosage and Administration (2.2) ].
Quoted from the official label, section “Geriatric Use”.
Side effects
- The most common adverse reactions are: headache, dizziness, constipation, and diarrhea.
- ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
- 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- Famotidine was studied in 7 U.S. and international placebo- and active-controlled trials in approximately 2500 patients [ see Clinical Studies (14) ] .
- A total of 1442 patients were treated with famotidine, including 302 treated with 40 mg twice daily, 456 treated with 20 mg twice daily, 461 treated with 40 mg once daily, and 396 treated with 20 mg once daily.
- The population was 17-91 years old, fairly well distributed between gender and race; however, the predominant race treated was Caucasian.
- The following adverse reactions occurred in greater than or equal to 1% of famotidine-treated patients:
- headache, dizziness and constipation.
- The following other adverse reactions were reported in less than 1% of patients in clinical trials:
- Body as a Whole :
- fever, asthenia, fatigue Cardiovascular :
- palpitations Gastrointestinal :
- elevated liver enzymes, vomiting, nausea, abdominal discomfort, anorexia, dry mouth Hematologic :
- thrombocytopenia Hypersensitivity :
- orbital edema, rash, conjunctival injection, bronchospasm Musculoskeletal :
- musculoskeletal pain, arthralgia Nervous System/Psychiatric :
- seizure, hallucinations, depression, anxiety, decreased libido, insomnia, somnolence Skin :
- pruritus, dry skin, flushing Special Senses :
- tinnitus, taste disorder Other :
- impotence
- 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of famotidine.
- Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Cardiovascular :
- arrhythmia, AV block, prolonged QT interval Gastrointestinal :
- cholestatic jaundice, hepatitis Hematologic :
- agranulocytosis, pancytopenia, leukopenia Hypersensitivity :
- anaphylaxis, angioedema, facial edema, urticaria Musculoskeletal :
- rhabdomyolysis, muscle cramps Nervous System/Psychiatric :
- confusion, agitation, paresthesia Respiratory :
- interstitial pneumonia Skin :
- toxic epidermal necrolysis/Stevens-Johnson syndrome
Quoted from the official label, section “Adverse Reactions”.
What to discuss with your doctor
- Central Nervous System (CNS) Adverse Reactions Advise elderly patients and those with moderate and severe renal impairment of the risk of CNS adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy [ see Warnings and Precautions (5.1) ] . Report symptoms immediately to a healthcare provider. QT Prolongation Advise patients with moderate and severe renal impairment of the risk of QT interval prolongation [ see Use in Specific Populations (8.6) ] . Report new cardiac symptoms, such as palpitations, fainting and dizziness or lightheadedness immediately to a healthcare provider. Administration Advise patients:
- Take famotidine tablets once daily before bedtime or twice daily in the morning and before bedtime, as recommended.
- Famotidine tablets may be taken with or without food.
- Famotidine tablets may be given with antacids. Manufactured by:
- MSN Laboratories Private Limited Telangana – 509 228, INDIA Distributed by:
- Novadoz Pharmaceuticals LLC Piscataway, NJ 08854-3714 Issued on :
- August 2024
Quoted from the official label, section “Patient Counseling Information”.
Strengths and forms
- FORMS AND STRENGTHS
- Famotidine Tablets USP, 20 mg are Light yellow to yellow, round, film-coated tablets debossed with “11” on one side and “plain”on other side.
- Famotidine Tablets USP, 40 mg are White, round, film-coated tablets debossed with “12” on one side and “plain” on other side. Tablets:
- 20 mg, 40 mg ( 3 )
Quoted from the official label, section “Dosage Forms & Strengths”.
What it looks like and how it is packed
- Famotidine Tablets USP, 20 mg are light yellow to yellow, round film-coated tablets debossed with ‘‘11‘’ on one side and ‘’plain’’ on the other side.
- Bottles of 30 NDC 72205-145-30 Bottles of 50 NDC 72205-145-50 Bottles of 75 NDC 72205-145-98 Bottles of 100 NDC 72205-145-91 Bottles of 500 NDC 72205-145-05 Bottles of 1,000 NDC 72205-145-99 Famotidine Tablets USP, 40 mg are white, round film-coated tablets debossed with ‘’12’’ on one side and ‘‘plain’’ on the other side.
- Bottles of 30 NDC 72205-146-30 Bottles of 100 NDC 72205-146-91 Bottles of 500 NDC 72205-146-05 Bottles of 1,000 NDC 72205-146-99 Storage
- Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
- Dispense in a USP tight, light-resistant container.
Quoted from the official label, section “How Supplied”.
What is in it
- The active ingredient in famotidine tablets USP is a histamine-2 (H 2 ) receptor antagonist.
- Famotidine is 3-[[2-(Diaminomethyleneamino)thiazol-4-yl]methylthio] -N'–Sulfamoylpropanimidamide.
- The molecular formula of famotidine is C 8 H 15 N 7 O 2 S 3 and its molecular weight is 337.45.
- Its structural formula is:
- Each famotidine tablet for oral administration contains either 20 mg or 40 mg of famotidine USP and the following inactive ingredients:
- corn starch, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide.
- In addition the 20 mg tablets contain iron oxide yellow.
- Famotidine USP is a White to yellowish-white, crystalline powder or crystals that is freely soluble in glacial acetic acid and dimethyl formamide, very slightly soluble in methanol, practically insoluble in ethanol and ethyl acetate.
- FDA approved dissolution test specifications differ from USP. str
Quoted from the official label, section “Description”.
Ingredients people check for
Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.
- Titanium dioxide
titanium dioxide
A whitening agent no longer allowed in food in the EU (E171).
Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.
Every version of this medicine (133)
The same active substance, strength and kind of form, from every company that sells it — with what each label lists.
Hide versions whose label lists:
Showing 80 of 80 (the first 80 are listed)
- FamotidineThis onePrescription onlyRedpharm DrugTitanium dioxide
- FamotidinePrescription onlyA-S Medication SolutionsTitanium dioxide
- FamotidinePrescription onlyA-S Medication SolutionsTitanium dioxide
- FamotidinePrescription onlyAdvanced Rx of Tennessee, LLCTitanium dioxide
- FamotidinePrescription onlyAdvanced Rx Pharmacy of Tennessee, LLCAlcohol (ethanol)Titanium dioxide
- FamotidineWithout prescriptionAlbertsons CompaniesTitanium dioxide
- FamotidinePrescription onlyAlembic Pharmaceuticals Inc.Alcohol (ethanol)SoyTitanium dioxide
- FamotidinePrescription onlyAlembic Pharmaceuticals LimitedSoyTitanium dioxide
- Acid ReducerWithout prescriptionAllegiant HealthTitanium dioxide
- Amazon Basic Care Acid ReducerWithout prescriptionAmazon.com Services LLCNo ingredient list on the stored label
- Basic Care Acid ReducerWithout prescriptionAmazon.com Services LLCLactoseTitanium dioxide
- Basic Care Heartburn PreventionWithout prescriptionAmazon.com Services LLCLactoseTitanium dioxide
- FamotidinePrescription onlyAmerican Health PackagingTitanium dioxide
- Careone Acid ReliefWithout prescriptionAmerican Sales CompanyLactose
- FamotidineWithout prescriptionAmerisource BergenTitanium dioxide
- FamotidinePrescription onlyAphena Pharma Solutions - Tennessee, LLCAlcohol (ethanol)SoyTitanium dioxide
- FamotidinePrescription onlyAscend Laboratories, LLCTitanium dioxide
- FamotidineWithout prescriptionAscent Pharmaceuticals, Inc.Titanium dioxide
- FamotidinePrescription onlyAsclemed USA, Inc.Titanium dioxide
- FamotidinePrescription onlyAurobindo Pharma LimitedTitanium dioxide
- FamotidineWithout prescriptionAurohealth LLCTitanium dioxide
- FamotidinePrescription onlyAvPAKNames none of these
- PepcidPrescription onlyBausch Health US LLCTitanium dioxide
- FamotidineWithout prescriptionBest ChoiceTitanium dioxide
- Maximum Strength Acid ControllerWithout prescriptionBETTER LIVING BRANDS LLC.Titanium dioxide
- FamotidineWithout prescriptionBetter Living Brands, LLCTitanium dioxide
- FamotidineWithout prescriptionBi-MartTitanium dioxide
- Berkley and Jensen FamotidineWithout prescriptionBJWCLactoseTitanium dioxide
- FamotidinePrescription onlyBluePoint LaboratoriesTitanium dioxide
- FamotidinePrescription onlyBryant Ranch PrepackTitanium dioxide
- FamotidinePrescription onlyBryant Ranch PrepackTitanium dioxide
- FamotidineWithout prescriptionCamber Consumer Care IncTitanium dioxide
- FamotidinePrescription onlyCamber Pharmaceuticals, Inc.Alcohol (ethanol)Titanium dioxide
- FamotidinePrescription onlyCardinal Health 107, LLCNames none of these
- Leader Acid ReducerWithout prescriptionCardinal Health 110, LLC. dba LeaderLactoseTitanium dioxide
- FamotidinePrescription onlyCarlsbad Technology, IncTitanium dioxide
- FamotidineWithout prescriptionChain Drug Consortium, LLCTitanium dioxide
- FamotidineWithout prescriptionChain Drug Marketing Association INCTitanium dioxide
- FamotidineWithout prescriptionCHAIN DRUG MARKETING ASSOCIATION, INC.Titanium dioxide
- FamotidinePrescription onlyChartwell RX, LLCAlcohol (ethanol)Titanium dioxide
- Zantac 360Without prescriptionChattem, Inc.Titanium dioxide
- Zantac 360 Cool MintWithout prescriptionChattem, Inc.Colour dyesTitanium dioxide
- FamotidinePrescription onlyContract Pharmacal Corp.Titanium dioxide
- Kirkland Signature Acid ControllerWithout prescriptionCostco Wholesale CompanyLactoseTitanium dioxide
- Acid ControllerWithout prescriptionCVS PharmacyLactoseTitanium dioxide
- Acid ReducerWithout prescriptionCVS PharmacyLactoseColour dyesTitanium dioxide
- FamotidineWithout prescriptionCVS Pharmacy, Inc.Titanium dioxide
- Acid ReducerWithout prescriptionCVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATEDLactoseTitanium dioxide
- FamotidinePrescription onlydirect rxAlcohol (ethanol)SoyTitanium dioxide
- FamotidinePrescription onlyDirect_RxNames none of these
- FamotidineWithout prescriptionDiscount Drug Mart, IncTitanium dioxide
- Dg Health Acid ReducerWithout prescriptionDolgencorp IncLactoseTitanium dioxide
- Dg Health Heartburn PreventionWithout prescriptionDolgencorp IncLactoseTitanium dioxide
- FamotidinePrescription onlyDr.Reddy's Laboratories LimitedNames none of these
- Acid Reducer Maximum StrengthWithout prescriptionDr.Reddys Laboratories Inc.Titanium dioxide
- FamotidineWithout prescriptionDr.Reddys Laboratories LimitedTitanium dioxide
- FamotidineWithout prescriptionFAMILY DOLLARTitanium dioxide
- FamotidineWithout prescriptionFamily Dollar Stores, Inc.Titanium dioxide
- FamotidineWithout prescriptionFamily Dollar Stores, LLCTitanium dioxide
- FamotidineWithout prescriptionFred's, Inc.Titanium dioxide
- FamotidineWithout prescriptionGeri-Care Pharmaceutical CorpTitanium dioxide
- FamotidineWithout prescriptionGLENMARK THERAPEUTICS INC., USATitanium dioxide
- FamotidinePrescription onlyGolden State Medical Supply, Inc.Titanium dioxide
- Acid ControllerWithout prescriptionH E BLactoseTitanium dioxide
- Acid ReducerWithout prescriptionH E BLactoseTitanium dioxide
- FamotidineWithout prescriptionHarris TeeterTitanium dioxide
- FamotidinePrescription onlyHAWAII REPACK, INC.Titanium dioxide
- Acid ReducerWithout prescriptionHyVee IncLactoseTitanium dioxide
- Zantac 360 2 Per Blister 6 BlistersWithout prescriptionJC World Bell Wholesale Co., Inc.Titanium dioxide
- Maximum Strength Pepcid Ac Icy Cool MintWithout prescriptionKenvue Brands LLCColour dyesTitanium dioxide
- Pepcid Ac Maximum StrengthWithout prescriptionKenvue Brands LLCTitanium dioxide
- Heartburn PreventionWithout prescriptionKroger CompanyLactoseTitanium dioxide
- Good Sense Acid ReducerWithout prescriptionL. Perrigo CompanyLactoseTitanium dioxide
- FamotidineWithout prescriptionLEADER/ CARDINAL HEALTH 110, INC.Titanium dioxide
- FamotidinePrescription onlyLegacy Pharmaceutical Packaging, LLCNames none of these
- FamotidinePrescription onlyLifestar Pharma LLCLactoseAlcohol (ethanol)Titanium dioxide
- Pepcid AcWithout prescriptionLil' Drug Store Products, Inc.Titanium dioxide
- FamotidineWithout prescriptionMagno-Humphries, Inc.Titanium dioxide
- FamotidinePrescription onlyMajor PharmaceuticalsNames none of these
- Major Heartburn Relief Maximum StrengthWithout prescriptionMajor PharmaceuticalsLactoseTitanium dioxide
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
Canada16 matching products
- ACID CONTROLLER MAXIMUM STRENGTH 20 mg · tabletWithout prescription2 makers
- FAMOTIDINE 20 mg · tablet2 makers
- ACID CONTROL 20 mg · tabletWithout prescription
- AURO-FAMOTIDINE 20 mg · tabletWithout prescription
- AURO-FAMOTIDINE MINT 20 mg · tabletWithout prescription
- FAMOTIDINE (ACID CONTROLLER) TABLETS 20 mg · tabletWithout prescription
- MAXIMUM STRENGTH PEPCID AC 20 mg · tabletWithout prescription
- AG-FAMOTIDINE 20 mg · tablet
Netherlands10 matching products
- Famotidine 20 mg Focus Care 20 mg · filmomhulde tablet
- Famotidine Aurobindo 20 mg 20 mg · filmomhulde tablet
- Famotidine Centrafarm 20 mg 20 mg · filmomhulde tablet
- Famotidine CF 20 mg 20 mg · filmomhulde tablet
- Famotidine Glenmark 20 mg 20 mg · filmomhulde tablet
- Famotidine Prolepha 20 mg 20 mg · filmomhulde tablet
- Famotidine Sandoz 20 mg 20 mg · filmomhulde tablet
- Famotidine Teva 20 mg 20 mg · filmomhulde tablet
Details
| Made by | Redpharm Drug |
|---|---|
| Active substance | Famotidine |
| Used in | Digestion, stomach, diabetes and nutrition |
| Strength | 20 mg |
| Form | Tablet, Film Coated |
| Route | Oral |
| Packs | 30 TABLET, FILM COATED in 1 BOTTLE |
| NDC | 67296-2186 |
| NDC | 67296-2264 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
187 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet, Film Coated100 products
- Tablet49 products
- Powder, for Suspension18 products
- Tablet, Coated7 products
40 mg3
40 mg · 3 companies
Show all forms · 8 forms
- Injection, Solution6 products
- 4 mg/mL
10 mg/mL4
- 20 mg/50mL
- Injection3 products
10 mg/mL3
10 mg/mL · 3 companies
- For Suspension3 products
40 mg/5mL3
40 mg/5mL · 3 companies
- Powder, for Solution1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.
Acid Controller20 mgWithout prescription Walgreen Company · FamotidineAcid Controller20 mgWithout prescription Safeway · FamotidineAcid Controller10 mgWithout prescription Safeway · FamotidineAcid Controller20 mgWithout prescription H E B · FamotidineAcid Controller10 mgWithout prescription H E B · FamotidineAcid Controller20 mgWithout prescription CVS Pharmacy · Famotidine